TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 674355
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting neuroleptic drugs (fluphenazine decanoate, flupenthixol decanoate, fluspirilene)
Study: 30795731
Drug: Tiotropium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (5 µg and 2.5 µg)
Study: 20939064
Drug: Placebo compliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo compliance (high compliance defined as taking 80% or more of dispensed study medication)
Study: 19335707
Drug: AZD6140 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 90 mg twice daily
Study: 19335707
Drug: AZD6140 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6140 180 mg twice daily
Study: 16710253
Drug: Spirapril (stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (stepwise antihypertensive therapy)
Study: 16710253
Drug: Hypotensive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive drugs (standard treatment)
Study: 7955818
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg mofegiline
Study: 7955818
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg mofegiline
Study: 7955818
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg mofegiline
Study: 29504258
Drug: Low-dose rhEPO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhEPO for 2 weeks
Study: 29504258
Drug: High-dose rhEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhEPO for 3 days
Study: 8823102
Drug: Heparin-coated surfaces
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated surfaces
Study: 8823102
Drug: Roller pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roller pump (heparin-coated circuits)
Study: 1878235
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% with fentanyl 50 micrograms in 10 ml of saline (Group 3, n = 15)
Study: 31827320
Drug: Esketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.5 mg/kg)
Study: 31827320
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine (1 mg/kg)
Study: 25683315
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin type A (BTX‐A) injection
Study: 20479765
Drug: Tesofensine (TE)
Normalized name: ethanol
DrugBank: Tesofensine (DB06156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tesofensine (TE) 2.0 mg daily for 7 days followed by 1.0 mg daily for 7 days
Study: 12028165
Drug: Oxybutynin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin group (2.5 mg daily to 5 mg three times a day)
Study: 9607264
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg once daily with diet
Study: 7899538
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg bid)
Study: 2223370
Drug: morphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine 0.1 mg kg‐1
Study: 2223370
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of morphine and alfentanil
Study: 31752751
Drug: 12-week intervention
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week intervention (weekly emails and social media posts)
Study: 25931799
Drug: Sevoflurane for
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane for inhalation anesthesia (I group)
Study: 25931799
Drug: Propofol for
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for total intravenous anesthesia (T group)
Study: 23663213
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (community program)
Study: 9697378
Drug: 2% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% pilocarpine four times daily
Study: 1551720
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g four times a day
Study: 4002788
Drug: muzolimine 20
Normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine 20 mg
Study: 4002788
Drug: muzolimine 40
Normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine 40 mg
Study: 24904116
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen B
Study: 24904116
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen C
Study: 18559233
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese drug (TCD) treatment with Huzhang Gout Granule and Jinhuang Ointment in acute stage; Yinlian Gout Granule in intermission.
Study: 18559233
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) treatment with diclofenac sodium dual release enteric-coated capsules in acute stage; benzbromarone or allopurinol in intermission.
Study: 18559233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TCD and WM treatment in acute stage and intermission.
Study: 18559233
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but implied as no treatment).
Study: 15612981
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg if body weight >30 kg; 10 mg if <30 kg) given pretransplant and at day 4; Tacrolimus (Tac) administered to obtain blood trough levels of 10-20 ng/ml during the first 2 months and 5-10 ng/ml thereafter; Steroids tapered during the first 6 months and replaced by mycophenolate mofetil (4-600 mg/m² body surface area) depending on previous rejection episodes, infection status, and routine biopsy results.
Study: 11422684
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of palpatory tenderness and clenching habit
Study: 8996129
Drug: Ketamine-midazolam (KM):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine-midazolam (KM): atropine 0.01 mg/kg, midazolam 0.05 mg/kg, ketamine 1.5 mg/kg
Study: 8996129
Drug: Meperidine-midazolam (MM):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine-midazolam (MM): meperidine 2 mg/kg, midazolam 0.1 mg/kg
Study: 7912103
Drug: Intravenous mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mivazerol 1 microgram/kg
Study: 7912103
Drug: Intravenous mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mivazerol 2 micrograms/kg
Study: 7912103
Drug: Intravenous mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous mivazerol 3 micrograms/kg
Study: 7912103
Drug: Oral mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mivazerol 800 micrograms
Study: 7912103
Drug: Oral mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mivazerol 1200 micrograms
Study: 7912103
Drug: Oral mivazerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mivazerol 1600 micrograms
Study: 3520390
Drug: Aminophylline and
Normalized name: aminophylline and adrenergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline and clenbuterol combination
Study: 31910393
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) for 8 weeks, 7 days per week, twice daily, using POWERbreathe KH1, starting at 50% of maximum inspiratory pressure with progressively increasing load
Study: 24958577
Drug: RDR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDR and PD20FEV1 combination
Study: 20546210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sufentanil with ropivacaine
Study: 18262758
Drug: Medroxyprogesterone acetate/megestrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate/megestrol acetate plus pharmacologic nutritional support plus L-carnitine plus thalidomide
Study: 12791112
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with 1.0 ml.kg‐1 body weight (BW) bupivacaine 0.25%
Study: 12791112
Drug: Wound instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound instillation with 0.2 ml.kg‐1 BW bupivacaine 0.5%
Study: 8806245
Drug: ethamsylate 500
Normalized name: ethamsylate 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethamsylate 500 mg six hourly
Study: 8806245
Drug: mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mefenamic acid 500 mg eight hourly
Study: 8806245
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid 1 g six hourly
Study: 1459517
Drug: pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine (100 mg/day)
Study: 1459517
Drug: pirenzepine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: pirenzepine (75 mg/day)
Study: 3901683
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose group (HDG) received 120‐160 mg furosemide daily for six weeks
Study: 3901683
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group (LDG) received 20‐40 mg furosemide daily for six weeks
Study: 30920098
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 0.2 mL of vitamin D3 (300,000 IU) into the base of mother wart for two sessions
Study: 27412942
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule (XFC), 3 capsules three times daily for 12 weeks
Study: 27412942
Drug: Sulfasalazine (SASP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (SASP), 4 tablets two times daily for 12 weeks
Study: 1596064
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lidocaine
Study: 22611998
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of lidocaine
Study: 22611998
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vs 200 mg lidocaine
Study: 16095507
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of 5‐methyl‐tetrahydrofolate
Study: 10072746
Drug: Standard program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard program (including rectal examination, fecal occult blood testing, and flexible sigmoidoscopy)
Study: 8533868
Drug: Neuroleptanaesthesia (NLA):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptanaesthesia (NLA): 7.1 mg droperidol and 0.008 mg/kg body weight fentanyl
Study: 8533868
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia with propofol (IVA): 493.4 mg propofol and 0.004 mg/kg body weight fentanyl
Study: 8533868
Drug: Balanced anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced anaesthesia (BAL): 2.6 mg droperidol and 0.004 mg/kg body weight fentanyl with 0.4 vol.% isoflurane
Study: 2148278
Drug: Enoximone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (2 X bolus 0.5 mg/kg; infusion 5.0 micrograms/kg/min)
Study: 28527788
Drug: Game-based inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Game-based inhibition training on a tablet for two months
Study: 17329193
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy for SCC
Study: 17329193
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy for adenocarcinoma
Study: 8864327
Drug: Phenytoin alone
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin alone (600 mg)
Study: 8864327
Drug: Phenytoin with
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin with atovaquone (600 mg phenytoin + 2000 mg atovaquone as two doses of 1000 mg)
Study: 6868097
Drug: Syringe and
Normalized name: KIT, SYRINGE AND TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe and needle (0.5 ml)
Study: 6868097
Drug: Jet-injector (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet-injector (0.1 ml)
Study: 6868097
Drug: Nose drops
Normalized name: Nose Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nose drops (0.5 ml)
Study: 30785053
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy for Insomnia (CBTI)
Study: 16172439
Drug: Specific program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific program administered by rheumatologists including education, protocol-based clinical management, and administrative duties.
Study: 11840225
Drug: Sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 20 mg once daily
Study: 2403062
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg vitamin A preparation
Study: 2403062
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vitamin A preparation
Study: 2403062
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg vitamin A preparation)
Study: 30168905
Drug: TAK-117 tablet
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-117 tablet (900 mg)
Study: 30168905
Drug: TAK-117 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-117 (600 mg) under fed conditions (high-fat meal)
Study: 30168905
Drug: TAK-117 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-117 (900 mg) plus lansoprazole
Study: 25318563
Drug: Standard HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HIV testing and referral for treatment (control)
Study: 22766124
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol 50 mg capsules (n = 35)
Study: 22766124
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 550 mg tablets (n = 34)
Study: 17350802
Drug: Zinc (Zn)
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc (Zn) 0.59 mg as zinc sulfate with 0.5 mg Fe as ferrous sulfate
Study: 17350802
Drug: Zinc (Zn)
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc (Zn) 11.71 mg as zinc sulfate with 10 mg Fe
Study: 17350802
Drug: Iron (Fe)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron (Fe) 0.5 mg as ferrous sulfate alone
Study: 17350802
Drug: Iron (Fe)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron (Fe) 10 mg alone
Study: 12050912
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) therapy (3 MU three times a week for 12 months)
Study: 11512193
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene and patient education in oral hygiene
Study: 1981905
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing 11 mg (-)-menthol
Study: 1981905
Drug: Candy placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candy placebo lozenge
Study: 23384256
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium infusion for 2 weeks followed by oral magnesium capsules for 4 weeks
Study: 21841065
Drug: Sclerosing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerosing treatment with polidocanol
Study: 19214120
Drug: Nevirapine twice
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine twice daily
Study: 10579480
Drug: R116301 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: R116301 (300 mg, oral administration)
Study: 1915428
Drug: Nicainoprol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicainoprol 400 mg
Study: 1915428
Drug: Nicainoprol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicainoprol 600 mg
Study: 1915428
Drug: Nicainoprol 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicainoprol 200 mg
Study: 31409515
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin (40 mg/day)
Study: 31409515
Drug: Low-dose rosuvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rosuvastatin (10 mg/day)
Study: 30661935
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (n=12) receiving weekly 15- to 30-minute telephone dietary counseling stressing 2.5 cups per week CVs and 3.5 cups per week GLVs.
Study: 30661935
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group (n=12) receiving weekly 15- to 30-minute telephone dietary counseling focusing on general healthy eating for cancer survivors.
Study: 21546436
Drug: Sildenafil 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 80 mg tid
Study: 11557911
Drug: Morphine-d3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-d3
Study: 9226314
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily irradiation (2 Gy/day to 66-70 Gy) or twice daily irradiation (1.25 Gy B.I.D. to 70-75 Gy) +/− planned neck dissection (for ≥ N2A disease)
Study: 3658552
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4), 6 mg elemental Mg/kg body weight, over 1 h
Study: 8650966
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine approaches in medical education
Study: 1348916
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg once a day
Study: 2946740
Drug: Nifedipine, 10
Normalized name: Nifedipine, 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 10 mg four times daily for 6 months
Study: 2946740
Drug: Placebo four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo four times daily for 6 months
Study: 30355395
Drug: Cooked cauliflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked cauliflower and cooked rice (CC+R)
Study: 30355395
Drug: Homogenised counterparts
Normalized name: Counteract IB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Homogenised counterparts of CE+R, CP+R, and CC+R
Study: 27207511
Drug: Metreleptin treatment
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin treatment
Study: 14760126
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at 100 mg/m2 or 50 mg/m2 concurrent with radiotherapy (70 Gy over 7 weeks)
Study: 11704374
Drug: Inhaled carbon
Normalized name: carbon dioxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled carbon monoxide (CO) at 1,200 ppm to 1,500 ppm
Study: 11704374
Drug: Inhaled air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled air
Study: 8065190
Drug: Histamine type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine type 2 receptor antagonists
Study: 8065190
Drug: Promotility agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promotility agents and surgical therapy
Study: 26142341
Drug: Danlou Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlou Tablet (4.5 g/day for 2 days before intervention, with a further 4.5 g/day for 90 days thereafter)
Study: 26142341
Drug: Danlou Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlou Tablet
Study: 22105265
Drug: Nonoxynol-9 vaginal
Normalized name: nonoxynol-9 Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 vaginal gel
Study: 16005801
Drug: Chamfer preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamfer preparation
Study: 16005801
Drug: 135 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 degrees shoulder preparation
Study: 16005801
Drug: 90 degrees
Normalized name: NEEDLE 22G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 degrees shoulder preparation
Study: 16005801
Drug: Gingival level
Normalized name: Bos taurus gingiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gingival level preparations
Study: 8585970
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (including nifedipine, verapamil, cinnarizine, tetrandrine)
Study: 204954
Drug: Exogenously administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenously administered oestrogens
Study: 22435613
Drug: Aloe whole
Normalized name: Aloe arborescens whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe whole leaf extract (AL with vitamins B(12), 1 mg and vitamin C 500 mg)
Study: 22435613
Drug: Aloe fillet
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe fillet gel (AG with B(12) 1 mg and vitamin C 500 mg)
Study: 22435613
Drug: Water (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (with vitamin B(12) 1 mg and vitamin C 500 mg)
Study: 19157139
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of traditional Chinese medicine (Changpikang) and ear acupoint therapy